ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer
March 30, 2020Infinity Pharmaceuticals said that IPI-549 in combination with nivolumab (Opdivo) has been given the fast track designation from the US Food and Drug Administration (FDA). -
Infinity Announces Start of Two IPI-549 Trials for Solid Tumors
September 05, 2019Infinity Pharmaceuticals announced the initiation of two clinical trials for IPI-549, a first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through ... -
Bristol-Myers Squibb and Infinity to collaborate on Opdivo (nivolumab) plus IPI-549 solid tumours study
May 08, 2019Bristol-Myers Squibb and Infinity will collaborate on a solid tumours trial to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s…
Pharma Sources Insight January 2025
